文献速递慢性肾脏病

生物标志物组合可区分儿童CKD进展风险

Biomarker Panels for Discriminating Risk of CKD Progression in Children.
PubMed 文献 · J Am Soc Nephrol · 2025-01-16

在CKiD前瞻性队列的599名6月龄至16岁CKD患儿中,采用回归树模型结合尿白蛋白/肌酐、尿EGF/肌酐、血浆KIM-1和eGFR识别出四个预后组。最高危组24名患儿全部发生CKD进展,中位时间1.3年;将风险分组加入临床模型后C统计量从0.76升至0.85。

要点

  • 尿白蛋白/肌酐与尿EGF/肌酐联合识别最高危组,该组24例全部进展。
  • 生物标志物组合加入临床风险因素后,C统计量从0.76提升至0.85。
  • 血浆KIM-1、尿白蛋白/肌酐、尿EGF/肌酐和eGFR构成有效生物标志物组合。

核心结论

  • 基于回归树的生物标志物组合(尿白蛋白/肌酐、尿EGF/肌酐、血浆KIM-1和eGFR)显著改善儿童CKD进展的区分度。

研究设计与样本

  • CKiD前瞻性队列研究,纳入599名6月龄至16岁、eGFR 30–90 ml/min per 1.73 m2的CKD患儿,测量入组后5个月的血浆和尿液生物标志物,主要结局为eGFR下降50%或肾衰竭复合终点。

主要发现

  • 中位年龄12岁(IQR 8–15),371名(62%)为男性,基线尿蛋白/肌酐比0.33 mg/mg(IQR 0.12–0.95),基线eGFR 53 ml/min per 1.73 m2(IQR 40–66)。
  • 205名儿童(34%)达到主要结局。
  • 最终模型中尿白蛋白/肌酐重要性最高,与尿EGF/肌酐共同识别最高危组24名儿童,100%发生CKD进展,中位时间1.3年(95%CI 1.0–1.7)。
  • 将回归树风险分组加入包含临床风险因素的预测模型后,C统计量从0.76(95%CI 0.71–0.80)提高至0.85(95%CI 0.81–0.88)。

临床怎么用

  • 在儿童CKD风险评估中,可考虑联合检测尿白蛋白/肌酐、尿EGF/肌酐、血浆KIM-1和eGFR以改善风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Plasma biomarkers (kidney injury molecule-1, KIM-1), urine biomarkers (EGF/creatinine and urine albumin-creatinine ratio), and eGFR identified four prognostic groups in children with CKD progression. A panel of biomarkers may better capture the complexity of kidney disease in children and may allow for a broader assessment of kidney health. BACKGROUND: We have previously studied biomarkers of tubular health (EGF), injury (kidney injury molecule-1 [KIM-1]), dysfunction (α-1 microglobulin), and inflammation (TNF receptor-1, TNF receptor-2, monocyte chemoattractant protein-1, YKL-40, and soluble urokinase plasminogen activator receptor) and demonstrated that plasma KIM-1, TNF receptor-1, TNF receptor-2, urine KIM-1, EGF, monocyte chemoattractant protein-1, and urine α-1 microglobulin are each independently associated with CKD progression in children. In this study, we used bootstrapped survival trees to identify a combination of biomarkers to predict CKD progression in children. METHODS: The Chronic Kidney Disease in Children (CKiD) Cohort Study prospectively enrolled children aged 6 months to 16 years with an eGFR of 30–90 ml/min per 1.73 m2. We measured biomarkers in stored plasma and urine collected 5 months after study enrollment. The primary outcome of CKD progression was a composite of 50% eGFR decline or kidney failure. We constructed a regression tree–based model for predicting the time to the composite event, using a panel of clinically relevant biomarkers with empirically derived thresholds, in addition to conventional risk factors. RESULTS: Of the 599 children included, the median age was 12 years (interquartile range [IQR], 8–15), 371 (62%) were male, baseline urine protein-creatinine ratio was 0.33 (IQR, 0.12–0.95) mg/mg, and baseline eGFR was 53 (IQR, 40–66) ml/min per 1.73 m2. Overall, 205 children (34%) reached the primary outcome of CKD progression. A single regression tree–based model using the most informative predictors with data-driven biomarker thresholds suggested a final set of four prognosis groups. In the final model, urine albumin/creatinine was the variable with the highest importance and along with urine EGF/creatinine identified the highest risk group of 24 children, 100% of whom developed CKD progression at a median time of 1.3 years (95% confidence interval [CI], 1.0 to 1.7). When the regression tree–derived risk group classifications were added to prediction models including the clinical risk factors, the C-statistic increased from 0.76 (95% CI, 0.71 to 0.80) to 0.85 (95% CI, 0.81 to 0.88). CONCLUSIONS: Using regression tree–based methods, we identified a biomarker panel of urine albumin/creatinine, urine EGF/creatinine, plasma KIM-1, and eGFR, which significantly improved discrimination for CKD progression.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Greenberg JH, Abraham AG, Xu Y, et al. Biomarker Panels for Discriminating Risk of CKD Progression in Children. J Am Soc Nephrol. 2025. PMID: 39820177. doi:10.1681/ASN.0000000602

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。